文献速递生殖医学

线粒体DNA定量作为胚胎活力评估工具:单整倍体囊胚移植数据的回顾性分析

Mitochondrial DNA quantification as a tool for embryo viability assessment: retrospective analysis of data from single euploid blastocyst transfers.
PubMed 文献 · Hum Reprod · 2017-01-01

这项盲法回顾性研究分析了490对夫妇的1505枚整倍体囊胚,评估线粒体DNA(mtDNA)水平能否独立于形态预测着床能力。139枚(9.2%)mtDNA水平超过既定阈值;已移植的282枚中,mtDNA正常者着床率为74.3%(185/249),而mtDNA升高者无一妊娠(0/33),阴性预测值为100%(33/33),两组着床率差异显著(P < 0.0001)。作者认为mtDNA定量可作为整倍体囊胚着床潜能的独立生物标志物,但需非选择研究和随机对照试验确定临床获益。

要点

  • 在1505枚整倍体囊胚中,9.2%(139/1505)的mtDNA水平超过既定活力阈值。
  • 已移植的282枚囊胚中,mtDNA正常者着床率为74.3%(185/249),mtDNA升高者为0%(0/33)。
  • mtDNA评估的阴性预测值为100%(33/33),两组着床率差异显著(P < 0.0001)。

核心结论

  • 研究结果强烈提示,超过既定阈值的mtDNA水平与囊胚着床失败强烈相关,是胚胎活力的独立生物标志物。
  • 作者认为mtDNA定量可作为评估囊胚活力的有用工具,但需非选择研究和随机对照试验确定临床获益的真实程度。

研究设计与样本

  • 大型盲法回顾性研究,分析490对夫妇经胚胎植入前非整倍体遗传学检测获得的1505枚整倍体囊胚的相对mtDNA水平。
  • 囊胚活检样本DNA扩增后经下一代测序或微阵列比较基因组杂交进行非整倍体分析,仅染色体正常胚胎接受mtDNA定量实时PCR检测,分析时不知胚胎移植结局。
  • 所有周期均移植单枚胚胎。

主要发现

  • 1505枚整倍体囊胚中9.2%(139/1505)mtDNA水平超过既定活力阈值,被预测着床机会降低。
  • 截至分析时共移植282枚整倍体囊胚,总着床率为65.6%(185/282);其中249枚mtDNA水平正常,185枚着床,着床率74.3%。
  • 33枚移植胚胎mtDNA水平升高,无一妊娠,mtDNA评估的阴性预测值为100%(33/33)。
  • mtDNA正常与升高胚胎的着床率差异显著(P < 0.0001)。
  • 用于胚胎分类的mtDNA阈值不受女性年龄或IVF所在诊所影响,胚胎形态变异不影响mtDNA升高的概率。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者指出,需开展非选择研究和随机对照试验等其他类型研究以确定任何临床获益的真实程度。
  • 作者建议开展前瞻性研究以证实这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the amount of mitochondrial DNA (mtDNA) in blastocyst biopsy specimens have the potential to serve as a biomarker of euploid embryo implantation ability, independent of morphology? SUMMARY ANSWER: The results of this study strongly suggest that elevated mtDNA levels, above a previously defined threshold, are strongly associated with blastocyst implantation failure and represent an independent biomarker of embryo viability. WHAT IS KNOWN ALREADY: Improved methods of embryo selection are highly desirable in order to increase the efficiency of IVF treatment. At present, even the transfer of chromosomally normal embryos of high morphological grade cannot guarantee that a pregnancy will follow. Recently, it has been proposed that the quantity of mtDNA in embryonic cells may be an indicator of developmental potential, with higher levels of mtDNA associated with reduced implantation. However, thus far reported data sets have been relatively small and in some cases have lacked appropriate validation. STUDY DESIGN, SIZE, DURATION: This large, blinded, retrospective study involved the analysis of relative mtDNA levels in 1505 euploid blastocysts obtained from 490 couples undergoing preimplantation genetic testing for aneuploidy. Implantation outcomes were compared to mtDNA levels in order to determine the capacity of the method to predict viability and to assess the validity of previously established thresholds. PARTICIPANTS/MATERIALS, SETTING, METHODS: DNA from blastocyst biopsy samples was amplified and then subjected to aneuploidy analysis using next generation sequencing or array comparative genomic hybridization. Only those embryos classified as chromosomally normal had their mtDNA levels assessed. This analysis was undertaken retrospectively using quantitative real-time PCR, without knowledge of the outcome of embryo transfer. Predictions of implantation failure, based upon mtDNA levels were subsequently compared to the observed clinical results. All cycles involved the transfer of a single embryo. MAIN RESULTS AND THE ROLE OF CHANCE: Of all blastocysts analyzed, 9.2% (139/1505) contained mtDNA levels above a previously established viability threshold and were therefore predicted to have reduced chances of implantation. To the date of analysis, 282 euploid blastocysts had been transferred with an overall implantation rate of 65.6% (185/282). Of the transferred embryos, 249 contained levels of mtDNA in the normal range, 185 of which produced a pregnancy, giving an implantation rate of 74.3% for euploid embryos with 'normal' quantities of mtDNA. However, 33 of the transferred embryos were determined to have elevated mtDNA quantities. None of these led to a pregnancy. Therefore, the negative predictive value of mtDNA assessment in this cohort was 100% (33/33). The difference between the implantation rates for embryos with normal and elevated mtDNA levels was highly significant (P < 0.0001). The mtDNA thresholds, used for classification of embryos, were unaffected by female age or the clinic in which the IVF was undertaken. The probability of an embryo having elevated levels of mtDNA was not influenced by variation in embryo morphology. LIMITATIONS, REASONS FOR CAUTION: This study provides strong evidence that mtDNA quantification can serve as a valuable tool to assist the evaluation of blastocyst viability. However, to determine the true extent of any clinical benefits, other types of investigations, such as non-selection studies and randomized controlled trials, will also be necessary. WIDER IMPLICATIONS OF THE FINDINGS: The results of this study suggest that mtDNA quantity can serve as an independent biomarker for the prediction of euploid blastocyst implantation potential. Prospective studies should now be undertaken to confirm these results. Additionally, investigations into the underlying biological cause(s) of elevated mtDNA levels and an enhanced understanding of how they relate to diminished implantation potential would be invaluable. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by funding provided by Reprogenetics. None of the authors have any competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Ravichandran K, McCaffrey C, Grifo J, et al. Mitochondrial DNA quantification as a tool for embryo viability assessment: retrospective analysis of data from single euploid blastocyst transfers. Hum Reprod. 2017. PMID: 28387858. doi:10.1093/humrep/dex070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。